MAPT and Alzheimer disease: Our previous study also demonstrated that in Aβ25–35-treated BV-2 cells, tau protein hyperphosphorylation and oxidative injury could be suppressed by agomelatine intervention, which suggested agomelatine may provide a neuroprotective effect in AD (Yao et al., 2019).